A carregar...
Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
KRAS mutation is frequently seen in a subtype of ovarian cancer categorized as type 1. The KRAS‐MAPK pathway, which is closely involved in type 1 cancer progression, is under the regulation of receptor tyrosine kinases (RTKs). AXL, one of the RTKs, has been reported to be overexpressed in ovarian ca...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7293078/ https://ncbi.nlm.nih.gov/pubmed/32291856 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14414 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|